Erythrokeratoderma variabilis and progressiva (EVP) is a rare genetic disorder characterized by inflammatory destruction of the skin with predominantly erythematous and keratotic manifestations. Enosmetic manifestations often lead to significant aesthetic and physical discomfort for patients, as well as high risks of concomitant infections. The disease can manifest itself in various forms, including chronic infectious complications, various dermatological conditions and systemic manifestations. Erythrokeratoderma varies in severity and clinical manifestations, making its diagnosis and treatment challenging for the medical community.
History of the disease and interesting historical facts
The history of erythrokeratoderma variabilis and progressiva goes back to observations of rare cases in the 19th century, when scientists began to identify patterns of skin diseases and classify them. One of the first mentions of this pathology is considered to be the description proposed by the French dermatologist Eugène Dupuytren in 1839. However, the first full clinical description of EVP was proposed in 1945 by the Australian dermatologist J. P. Bailey. Over time, researchers began to pay attention to the hereditary aspects of the disease, as well as its relationship with immune and metabolic disorders. In 1995, a mutation in the gene responsible for this disease was identified, which was a significant step forward in understanding its pathogenesis. At the moment, thanks to modern genetic technologies, new aspects of hereditary predisposition and molecular pathology of EVP are being studied, which may change approaches to the diagnosis and treatment of this disease.
Epidemiology
Erythrokeratoderma variabilis and progressiva is extremely rare in the population. Statistics show that the incidence is about 1 case per 100,000–250,000 people. In most cases, EVP is diagnosed in childhood, but individual cases are also registered in adults. There is no gender predisposition to the disease, and it occurs in both men and women with equal frequency. There is evidence that the incidence is higher in certain ethnic groups and among certain geographic populations, which may indicate the presence of factors contributing to the development of the disease in these groups.
Genetic predisposition to this disease
Erythrokeratoderma variabilis and progressiva has a genetic origin associated with mutations in specific genes. The most well-known are mutations in the KRT1 and KRT10 genes, which belong to the genus of keratins, which play a key role in the structural stability and functional integrity of skin barriers. Autoimmune phenomena, including abnormal expression of proinflammatory cytokines, may also contribute to the pathogenesis of EVP. Some studies indicate possible associations with other genetic disorders, such as Noonan syndrome and other structural dermatoses. Erectile dysfunction mutations inherited in an autosomal recessive manner significantly increase the risk of developing this syndrome, which emphasizes the importance of genetic counseling for family members of the patient.
Risk factors for the development of this disease
Risk factors that contribute to the development of erythrokeratoderma variabilis and progressive can be divided into physical and chemical. Physical risk factors include:
- Solar radiation, which damages the skin and worsens the symptoms of the disease.
- Skin trauma that may worsen symptoms or lead to secondary infections.
- Contact with irritants or allergens that increase the risk of inflammatory reactions.
Chemicals to which patients with EVP may be exposed include:
- Synthetic detergents and cosmetics containing aggressive components.
- Professional chemicals used in various industries and causing allergic reactions or dermatitis.
In addition, there are social factors, such as stress or lack of access to quality health care, that can increase symptoms and worsen the overall health of people with EVP.
Diagnosis of this disease
Diagnosis of erythrokeratoderma variabilis and progressive requires a comprehensive approach, including clinical assessment, medical history and laboratory tests. The main symptoms of the disease are:
- Intense erythema, especially over large areas of skin.
- Thickening of the skin with areas of keratosis.
- Combination with itching and burning.
- The likelihood of developing secondary infections.
Laboratory tests may include:
- Blood tests to check for inflammatory markers and infections.
- Skin biopsy to confirm the diagnosis and rule out other diseases.
Radiological examinations are rarely used but may be useful to evaluate the skin in severe cases. Other diagnostics include genetic testing for mutations associated with EVP.
Differential diagnosis is important to exclude other dermatological conditions such as psoriasis, eczema and other hereditary dermatoses, which requires careful analysis of the clinical picture and laboratory data.
Treatment
Treatment of erythrokeratoderma variabilis and progressiva should be comprehensive and individualized. General treatment includes:
- Immunosuppressive drugs aimed at reducing the inflammatory response.
- Corticosteroids to reduce erythema and itching.
- Systemic retinoids to normalize skin keratinization processes.
Pharmacological treatment may include:
- Nonsteroidal anti-inflammatory drugs to relieve inflammation.
- Antibiotics and antiseptics for the prevention and treatment of secondary infections.
Surgical treatment may be considered in extreme cases where significant complications arise, such as ulceration or infected skin areas. Other treatments include physical therapy and the use of special cosmetics to care for the affected skin.
List of medications used to treat this disease
The main medications used for erythrokeratoderma variabilis and progressive include:
- Methotrexate.
- Acitretin.
- Prednisolone.
- Klimastin.
- Cyclosporine A.
- Topical corticosteroids.
- Azathioprine.
- Desloratadine.
These drugs are selected depending on the severity of the disease and the individual characteristics of the patient.
Disease monitoring
Monitoring of erythrokeratoderma variabilis and progressive includes regular examinations by a dermatologist, monitoring of laboratory parameters and assessment of the patient's quality of life. It is important to monitor:
- Dynamics of clinical manifestations.
- Response to treatment.
- The occurrence of possible complications, such as infections or the development of other diseases.
The prognosis with proper treatment can be favorable, but patients often experience exacerbations, which requires constant routine monitoring. Complications can include infectious skin lesions and the development of secondary dermatitis.
Age-related features of the disease
Erythrokeratoderma variabilis and progressive can manifest in different age groups, but most often it manifests itself in childhood and adolescence. In children, the disease can have a more acute course, with a pronounced reaction to all external factors, while in adults it can manifest itself in the form of chronicity of the process with less pronounced symptoms. In addition, depending on age, the approach to treatment and the use of drugs may change, which is due to different physiological characteristics and reactions to therapy.
Questions and Answers
- What is erythrokeratoderma variabilis and progressive? This is a rare skin condition characterized by inflammatory changes, erythema and keratosis. It can cause significant discomfort and inflammation of the skin.
- What are the main symptoms of the disease? The main symptoms include intense erythema, itching, keratosis and the possibility of developing secondary infections in the affected skin area.
- Is this disease difficult to diagnose? Yes, diagnosis can be challenging as erythrokeratoderma variabilis and progressiva requires differential diagnosis with other dermatological conditions.
- Are there any effective treatments for the disease? Treatment may include immunosuppressive drugs, corticosteroids, and systemic retinoids, but requires an individual approach for each patient.
- What is the prognosis for the disease? The prognosis can be favorable with proper treatment, but exacerbations and complications are possible, which requires constant monitoring.
Dr. Oleg Korzhikov, an experienced dermatologist, recommends paying special attention to skin care for erythrokeratoderma variabilis and progressive. He advises:
- Use hypoallergenic cosmetics and soap to avoid irritation.
- Regularly consult a dermatologist to monitor the condition of the skin and correct therapy.
- Record and document any changes in skin condition to analyze their causes.
- Avoid excessive exposure to sunlight and use sunscreen.
- Maintaining a healthy lifestyle, including a balanced diet and physical activity, can have a positive effect on the condition of your skin.
These recommendations can help minimize disease symptoms and improve the quality of life of patients with erythrokeratoderma variabilis and progressive.
